Further, we developed the clinically relevant syngeneic LLC orthotopic mouse model of lung cancer to verify the tumor biology characteristics of LLC-SD after Mek1/2 or p110 knockdown. This evidence concerns the gene MAP2K1 and lung carcinoma.